JP Morgan Downgrades Upstream Bio to Neutral, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 90.2%

Neg 90.2% Neu 0% Pos 0%

JP Morgan analyst Tessa Romero downgrades Upstream Bio (NASDAQ:UPB) from Overweight to Neutral and lowers the price target from $35 to $8.